Publications by authors named "A Kartolo"

Background: Head and squamous cell carcinoma (HNSCC) in the locally advanced setting is challenging to treat and remains an area of significant morbidity and mortality. For patients who are cisplatin-ineligible and considered unresectable, there is no clear standard of care including the choice of radiosensitizer.

Methods: OVID Medline, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched.

View Article and Find Full Text PDF
Article Synopsis
  • About 30% of people with non-small cell lung cancers (NSCLC) have stage III cancer when they find out they're sick, and half of them get treated with special chemotherapy and radiation.
  • A study looked at 195 patients treated from 2010 to 2021 to see what factors affect their chances of getting brain cancer after treatment.
  • Out of these patients, many had complications; 43% got any kind of cancer spread and 17% developed brain cancer, especially if they had more severe disease or certain treatment-related factors.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how the timing of immune checkpoint inhibitors (ICIs) affects patient outcomes in advanced melanoma.
  • Patients who received all their initial ICI infusions in the afternoon showed significantly worse overall and progression-free survival compared to those who had at least one morning infusion.
  • A recommendation is made that scheduling ICI treatments in the morning could potentially improve survival rates for patients.
View Article and Find Full Text PDF

The aim of this study was to evaluate overall survival post-treatment discontinuation survival (OS PTD ) in advanced melanoma patients started on immunotherapy. This retrospective study included all unresectable advanced or metastatic melanoma patients who had permanent treatment discontinuation after receiving at least one cycle of palliative-intent programmed death-1 ± cytotoxic T-lymphocyte associated protein-4 inhibitor treatment from 2014 to 2019. Indications of permanent treatment discontinuation included treatment completion, toxicity or progression.

View Article and Find Full Text PDF